ROQ.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ROQ.L in your mock portfolio yet.
Roquefort Therapeutics is currently loss-making, as reflected by its negative EPS and negative P/E ratio, indicating the absence of positive earnings to support valuation. The small absolute loss per share suggests an early-stage or pre-commercial profile rather than a mature, profitable business. Overall, the lack of profitability and earnings visibility tilts the financial picture to the bearish side from a fundamentals standpoint.
The stock is flat over the last month, suggesting a lack of strong buying momentum or new catalysts in the near term. Trading below its 200-day moving average points to a prevailing longer-term downtrend, even though the RSI near 60 indicates neither oversold nor overbought conditions. Taken together, the technical setup leans bearish to mildly negative, with price action still below a key long-term resistance level.
Social media traction appears modest and largely stagnant, with only marginal growth in followers across Twitter/X and LinkedIn. This indicates limited expansion in investor or stakeholder engagement and no clear surge in market interest. While not outright negative, the slow growth in digital presence does not provide a strong bullish signal for near-term stock performance.
Roquefort Therapeutics currently presents a bearish overall profile, driven by its loss-making status and a share price trading below its 200-day moving average. While momentum is not severely negative and alternative data are not signaling a collapse in interest, there is also no strong evidence of accelerating fundamentals or investor engagement. Until profitability prospects or clear growth catalysts emerge, the risk/reward skews to the downside or, at best, a prolonged period of sideways trading.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: